Trial Outcomes & Findings for Clinical Evaluation of Using Intense Pulsed Light for Improving the Appearance of Striae Distensae (NCT NCT02452359)

NCT ID: NCT02452359

Last Updated: 2020-11-03

Results Overview

Striae distensae appearance improvement by at least 1 point on the Global Aesthetic Improvement scale (GAIS) from photographs 3 months following the last treatment as determined by 3 blinded reviewers where 3 = Very Much Improved, 2 = Much Improved, 1 = Improved, 0 = No Change, -1 = Worse, -2 = Much Worse and -3 = Very Much Worse.

Recruitment status

TERMINATED

Study phase

NA

Target enrollment

54 participants

Primary outcome timeframe

90 days following last IPL treatment

Results posted on

2020-11-03

Participant Flow

Each subject to receive IPL 580 nm treatment to striae distensae on either abdomen or thighs. Baseline photos taken of untreated treatment area.

Participant milestones

Participant milestones
Measure
IPL 580 nm Treatment
Each subject to receive IPL applicator SR580 treatment of Striae Distensae either on the abdomen or thighs.
Overall Study
STARTED
54
Overall Study
COMPLETED
33
Overall Study
NOT COMPLETED
21

Reasons for withdrawal

Reasons for withdrawal
Measure
IPL 580 nm Treatment
Each subject to receive IPL applicator SR580 treatment of Striae Distensae either on the abdomen or thighs.
Overall Study
Adverse Event
1
Overall Study
Lost to Follow-up
15
Overall Study
Pregnancy
1
Overall Study
Withdrawal by Subject
4

Baseline Characteristics

The baseline photographs were not evaluated.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Treatment Group
n=54 Participants
Group receiving treatment with Venus Versa IPL energy Venus Versa: The Venus Versa system consists of a console and 4 detachable applicators that deliver optical energy in the form of Intense Pulsed Light to the patient skin. The intense pulsed light lamp delivers non-coherent light distributed over a range of wavelengths from 500 nm to 1200 nm. Different filters are embedded in the different applicators so that each applicator can deliver the desired spectrum according to the indications to be treated.In this study, the IPL applicator SR580 will be evaluated for the treatment of Striae Distensae, depending on the patient's skin type. IPL gel: water based gel used to protect the skin during light based treatments. Is also commonly used during ultrasound treatments.
Age, Categorical
<=18 years
0 Participants
n=54 Participants
Age, Categorical
Between 18 and 65 years
54 Participants
n=54 Participants
Age, Categorical
>=65 years
0 Participants
n=54 Participants
Sex/Gender, Customized
Male
1 Participants
n=54 Participants
Sex/Gender, Customized
Female
32 Participants
n=54 Participants
Sex/Gender, Customized
Unknown
21 Participants
n=54 Participants
Race/Ethnicity, Customized
Hispanic
6 Participants
n=54 Participants
Race/Ethnicity, Customized
Caucasian
25 Participants
n=54 Participants
Race/Ethnicity, Customized
Other
1 Participants
n=54 Participants
Race/Ethnicity, Customized
unknown
22 Participants
n=54 Participants
Baseline photograph of treatment area
0 Participants
The baseline photographs were not evaluated.

PRIMARY outcome

Timeframe: 90 days following last IPL treatment

Population: The primary outcome measure is not reported as data not collected.

Striae distensae appearance improvement by at least 1 point on the Global Aesthetic Improvement scale (GAIS) from photographs 3 months following the last treatment as determined by 3 blinded reviewers where 3 = Very Much Improved, 2 = Much Improved, 1 = Improved, 0 = No Change, -1 = Worse, -2 = Much Worse and -3 = Very Much Worse.

Outcome measures

Outcome data not reported

Adverse Events

IPL 580 nm Treatment

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Yoni Iger

Venus Concept Ltd

Phone: 888-907-0115

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place